背景:DNA甲基化在癌变过程中起着重要作用,programming,和各种人类癌症的预后。RASSF1A,BRCA1,APC,p16是卵巢癌患者中经常甲基化的基因。因此,我们的研究旨在更好地确定RASSF1A的预后和癌症特征的影响,BRCA1,APC,和p16启动子甲基化在卵巢癌患者。
方法:数据库,如PubMed、WebofScience,EMBASE,CNKI,和万方在2024年3月4日之前被搜索发表的研究。结果显示为OR和HR,CI为95%。然后,采用随机或固定效应模型评估效应大小.
结果:最后,本荟萃分析包括27篇文章。RASSF1A之间没有观察到显著的关系,BRCA1和APC启动子甲基化与临床预后(包括总生存期和无进展生存期)和癌症特征(包括腹水,淋巴结转移,和盆腔腹膜转移)在卵巢癌中。p16启动子甲基化与不良PFS(HR=1.52,95%CI=1.14~2.04)和OS(HR=1.39,95%CI=1.06~1.83)显著相关,多变量Cox回归模型的PFS较差(HR=1.42,95%CI=1.05~1.92)。此外,我们的结果表明,临床分期与OS差相关,而肿瘤分级与OS无显著相关性.
结论:RASSF1A,BRCA1和APC启动子甲基化与临床预后和癌症特征没有显着相关。P16可能是预测卵巢癌PFS的有用生物标志物。此外,临床分期与OS显著相关.在进一步的研究中,仍需要更多前瞻性和多中心验证研究.
BACKGROUND: DNA methylation plays an important role in the carcinogenesis, progression, and prognosis of various human cancers. RASSF1A, BRCA1,
APC, and p16 are the frequently methylated genes among patients with ovarian cancer. Therefore, our study aimed to better determine the prognostic and cancer characteristics effects of RASSF1A, BRCA1,
APC, and p16 promoter methylation in ovarian cancer patients.
METHODS: Databases such as PubMed, Web of Science, EMBASE, CNKI, and WanFang were searched for published studies up to March 4, 2024. The outcomes are shown as OR and HR with their 95% CIs. Then, the random or fixed-effect model was performed to evaluate the effect sizes.
RESULTS: Finally, 27 articles were included in this meta-analysis. No significant relationships were observed between RASSF1A, BRCA1, and
APC promoter methylation and the clinical prognostic (including overall survival and progression-free survival) and cancer characteristics (including ascites, lymph node metastasis, and pelvic peritoneal metastasis) in ovarian cancer. p16 promoter methylation was significantly related to poor progression-free survival (PFS) (HR = 1.52, 95% CI = 1.14-2.04) and overall survival (OS) (HR = 1.39, 95% CI = 1.06, to 1.83) in univariate and poor PFS in multivariate Cox regression models (HR = 1.42, 95% CI = 1.05-1.92). Besides, our results indicated that the clinical stage was associated with inferior OS while there was no significant association between tumor grade and OS.
CONCLUSIONS: RASSF1A, BRCA1, and
APC promoter methylation were not significantly associated with clinical prognostic and cancer characteristics. p16 may be a useful biomarker for predicting PFS in ovarian cancer. Furthermore, the clinical stage was significantly associated with OS. In further research, more prospective and multicenter validation studies remain needed.